Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Study links rosiglitazone with MI

  • Comment
Rosiglitazone, a drug commonly used to treat diabetes, is associated with an increased risk of myocardial infarction, a study has shown.

Rosiglitazone, a drug commonly used to treat diabetes, is associated with an increased risk of myocardial infarction, a study has shown.

The debate about the safety of the drug, manufactured by GlaxoSmithKline under the trade name Avandia, has been raging since the US Food and Drugs Administration issued a warning about the possible risk in February this year.

A previous study in the New England Journal of Medicine had warned of an increased risk of MI with rosiglitazone earlier this year.

The latest research pools data from four previous studies on rosiglitazone and found the drug increased the risk of MI by 42% and more than doubled the risk of heart failure. There was no increased risk of cardiovascular mortality.

But a spokesperson for GSK said: 'The JAMA article on rosiglitazone is yet another iteration of previously analysed data, and offers no new information on the safety of rosiglitazone.'

Journal of the American Medical Association (2007) 298:1189-1195

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.